Bicara Therapeutics insider cashes in options; retains 158k options
Rhea-AI Filing Summary
Bicara Therapeutics Inc. (BCAX) – Form 4 insider filing dated 18 Jun 2025 reports transactions by Chief Legal Officer Lara Meisner.
Non-derivative activity: On 16 Jun 2025 Meisner exercised 15,829 options for common stock at an exercise price of $5.45 per share and immediately sold the same 15,829 shares at a weighted-average price of $10.43 (individual sales executed between $10.03-$10.84). As a result, her direct common-stock ownership fell to 0 shares.
Derivative holdings: Two option grants were partially exercised. After the transactions Meisner still directly holds 60,854 options with a $5.45 strike expiring 10 Dec 2033 and 97,443 options with the same strike and expiry, for a total of 158,297 remaining options.
- Grant #1 vests in 16 equal quarterly installments from 14 Dec 2023.
- Grant #2 vested 25 % on 27 Nov 2024; the balance vests in 12 equal quarterly installments thereafter.
Rule 10b5-1 plan: All trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 13 Nov 2024, as disclosed in the Explanation of Responses.
The filing reflects routine option exercise and monetisation by an executive officer, with no change to derivative exposure but the elimination of directly held common shares.
Positive
- Executive retains 158,297 in-the-money options, maintaining long-term alignment with shareholder value.
Negative
- Officer sold 15,829 shares immediately after exercise, reducing direct ownership to zero and signalling limited near-term commitment.
Insights
TL;DR: Officer exercises options, sells shares; maintains large option stake—neutral signal.
The transaction shows Meisner converting 15,829 options at $5.45 and liquidating the resulting shares at ≈$10.43, capturing a ~$4.98 spread. Because the sale fully offset the exercise, her direct equity stake is now nil, which can be viewed as mildly bearish on near-term price. However, she retains 158,297 options (strike $5.45, expiry Dec-2033), preserving long-term upside alignment. The pre-scheduled 10b5-1 plan mitigates concerns about timing. From a materiality standpoint, the share count is small relative to typical public-float levels, so the impact on valuation or float is negligible. Overall, the filing is informative but not a catalyst.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 6,085 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 9,744 | $0.00 | -- |
| Exercise | Common Stock | 15,829 | $5.45 | $86K |
| Sale | Common Stock | 15,829 | $10.43 | $165K |
Footnotes (1)
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
